23 November 2018
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL.
The Extraordinary General Meeting of Immunicum AB (publ) ("Immunicum" or the "Company") on 8 November 2018 resolved, in accordance with the Board's proposal from 16 October 2018, to implement a Rights Issue for existing shareholders (the "Rights Issue") and a Directed Issue (the "Directed Issue"). In connection with the Rights Issue and the Directed Issue (the "Share Issues"), the Board has prepared a prospectus that today, 23 November 2018, has been approved and registered by Finansinspektionen (the Swedish Financial Supervisory Authority) and subsequently published by the Company. The prospectus, containing full terms and conditions, and subscription forms are available on the Company's website (www.immunicum.se) as well as on Erik Penser Bank AB's website www.penser.se.
The Share Issues in Short
Time plan for the Rights Issue
21 November, 2018 Record date
26 November - 6 December, 2018 Trading in subscription rights on Nasdaq Stockholm
26 November - 10 December, 2018 Subscription period
Around 13 December, 2018 Publication of the outcome in the Rights Issue
Week 3, 2019 Estimated registration of the Share Issues with Bolagsverket (the Swedish Companies Registration Office)
Presentations
In connection with the Share Issues, the Company will present its business plan on the following occasions:
Financial, Strategic and Legal Advisor
Erik Penser Bank is the financial advisor and Asperia AB is the strategic advisor to Immunicum in connection with the Share Issues. Furthermore, Advokatfirman Delphi is the legal advisor to the Company in connection with the Share Issues.
This information is information that Immunicum AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 11.15 am CET on 23 November 2018.
Carlos de Sousa, CEO, Immunicum
Telephone: +46 31 41 50 52
E-mail: info@immunicum.com
Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com
Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540 or +49 892 388 7730
E-mail: ir@immunicum.com
About Immunicum AB (publ)Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com |